Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes

Patients with relapsed or refractory acute myelogenous leukemia (AML) have limited treatment options and a generally poor prognosis. The outcomes after allogeneic hematopoietic stem cell transplantation (HSCT) are poor in such patients [1 –4]. Additional medical interventions to induce remission have been exhausted in most cases. Adoptive cell therapy using donor cells from partially matched related donors has been used to induce an antileukemic effect without durable engraftment [5]. Guo et al [6,7] reported this approach for trea tment of older patients with AML with encouraging response rates.

Source: Biology of Blood and Marrow Transplantation - November 8, 2018 Category: Hematology Authors: Usama Gergis, Emeline Masson Frenet, Tsiporah Shore, Sebastian Mayer, Adrienne Phillips, Jing-Mei Hsu, Gail Roboz, Ellen Ritchie, Joseph Scandura, Sangmin Lee, Pinkal Desai, Michael Samuel, Jeffrey Ball, Anthony Blanco, Cynthia Romeo, Maria S Albano, Ludy Source Type: research